Ocugen (OCGN) Q2 2024 earnings summary

Executive summary

• Advanced gene therapy platform with clinical programs OCU400, OCU410, and OCU410ST progressing, including OCU400 Phase 3 dosing for RP and expanded access approval.

• OCU410 and OCU410ST are in Phase 1/2 trials, with high-dose cohorts completed and preliminary safety/efficacy data for OCU410 expected later in 2024.

• NeoCart is Phase 3-ready, and OCU500 (COVID-19 vaccine) is in early clinical collaboration.

• Successful $32.6M fundraising extends cash runway into Q3 2025 and strengthens shareholder base.

• Inclusion in the Russell Index in June 2024 increases visibility and supports long-term growth strategy.

Financial highlights

• Cash, cash equivalents, and restricted cash totaled $16.0M as of June 30, 2024, down from $39.5M at year-end 2023.

• Revenue for Q2 2024 was $1.1M, up from $0.5M in Q2 2023.

• Net loss for Q2 2024 was $15.3M, improved from $23.1M in Q2 2023; net loss per share was $0.04, compared to $0.10 in Q2 2023.

• Total operating expenses for Q2 2024 were $16.6M, down from $24.0M in Q2 2023.

• 257.4M shares of common stock outstanding as of June 30, 2024.

Outlook and guidance

• Cash runway extended into Q3 2025 following $32.6M fundraising; additional capital will be needed beyond that period.

• OCU400 Phase 3 on track for 2026 BLA and MAA submissions, with potential approvals in late 2026.

• OCU410 preliminary safety and efficacy data expected later in 2024.

• Management evaluating further funding strategies, including equity/debt placements, partnerships, and grants.

• Substantial doubt exists about ability to continue as a going concern within one year without further financing.